MX2022013237A - Maltodextrinas entrelazadas para el suministro oral de activos biologicos. - Google Patents

Maltodextrinas entrelazadas para el suministro oral de activos biologicos.

Info

Publication number
MX2022013237A
MX2022013237A MX2022013237A MX2022013237A MX2022013237A MX 2022013237 A MX2022013237 A MX 2022013237A MX 2022013237 A MX2022013237 A MX 2022013237A MX 2022013237 A MX2022013237 A MX 2022013237A MX 2022013237 A MX2022013237 A MX 2022013237A
Authority
MX
Mexico
Prior art keywords
linked
cross
maltodextrins
oral delivery
biological actives
Prior art date
Application number
MX2022013237A
Other languages
English (en)
Inventor
Francesco Trotta
Roberta Cavalli
Fabrizio Caldera
Monica Argenziano
Maria Tannous
Original Assignee
Roquette Freres
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roquette Freres filed Critical Roquette Freres
Publication of MX2022013237A publication Critical patent/MX2022013237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a la administración oral de activos biológicos, en particular de insulina, que comprende el uso de un material almidonado entrelazado como un sistema de suministro.
MX2022013237A 2017-07-12 2020-01-10 Maltodextrinas entrelazadas para el suministro oral de activos biologicos. MX2022013237A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17290094.6A EP3427725A1 (en) 2017-07-12 2017-07-12 Cross-linked maltodextrins for the oral delivery of biological actives

Publications (1)

Publication Number Publication Date
MX2022013237A true MX2022013237A (es) 2022-11-14

Family

ID=59649627

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000374A MX2020000374A (es) 2017-07-12 2018-07-11 Maltodextrinas entrelazadas para el suministro oral de activos biológicos.
MX2022013237A MX2022013237A (es) 2017-07-12 2020-01-10 Maltodextrinas entrelazadas para el suministro oral de activos biologicos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020000374A MX2020000374A (es) 2017-07-12 2018-07-11 Maltodextrinas entrelazadas para el suministro oral de activos biológicos.

Country Status (8)

Country Link
US (2) US11844838B2 (es)
EP (2) EP3427725A1 (es)
JP (2) JP7291682B2 (es)
CN (2) CN116159146A (es)
BR (1) BR112020000599A2 (es)
CA (1) CA3069628A1 (es)
MX (2) MX2020000374A (es)
WO (1) WO2019011964A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4164600A1 (en) 2020-06-16 2023-04-19 Roquette Freres Crosslinked starch derivative-based matrix

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001242732B2 (en) 2001-02-26 2006-08-24 Council Of Scientific And Industrial Research Carrier systems comprising vitamin B12-biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
CN103583696A (zh) 2003-06-20 2014-02-19 努特里尼亚有限公司 生物活性化合物保护方法及含有其的组合物
FR2918845B1 (fr) * 2007-07-19 2012-11-30 Roquette Freres Agent d'encapsulation comprenant une maltodextrine de pois et/ou un sirop de glucose de pois,compositions le contenant et son procede de preparation
CN102144976A (zh) * 2011-01-19 2011-08-10 谢坤 用“微胶囊”技术制备口服胰岛素干粉的方法
US20150086622A1 (en) 2012-04-18 2015-03-26 Nutrinia Ltd. Growth enhancement of infants
ITBO20120710A1 (it) 2012-12-28 2014-06-29 Univ Degli Studi Torino Sistema di veicolazione per l'insulina
WO2015111062A1 (en) * 2014-01-27 2015-07-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoencapsulation of hydrophilic active compounds
WO2016004974A1 (en) * 2014-07-07 2016-01-14 Roquette Italia S.P.A. A polymer based on a maltodextrin for encapsulating organic compounds
CN104353062A (zh) * 2014-11-21 2015-02-18 中国人民解放军南京军区福州总医院 一种胰岛素口服纳米制剂及其制备方法

Also Published As

Publication number Publication date
EP3651742A1 (en) 2020-05-20
EP3427725A1 (en) 2019-01-16
US20240066130A1 (en) 2024-02-29
CA3069628A1 (en) 2019-01-17
CN111417387B (zh) 2022-12-23
MX2020000374A (es) 2020-08-17
JP2023082010A (ja) 2023-06-13
US11844838B2 (en) 2023-12-19
JP7291682B2 (ja) 2023-06-15
WO2019011964A1 (en) 2019-01-17
JP2020526555A (ja) 2020-08-31
BR112020000599A2 (pt) 2020-07-14
CN116159146A (zh) 2023-05-26
US20210085795A1 (en) 2021-03-25
CN111417387A (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
MX2020013881A (es) Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.
CA2956871C (en) Compounds active towards bromodomains
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
MX2021001442A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EP3094343A4 (en) Rapid action insulin formulations and pharmaceutical delivery systems
MD4589C1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
MY166518A (en) Nanocapsules containing microemulsions
EP3150202A4 (en) Drug carrier for tumour-specific targeted drug delivery and use thereof
EP3313499A4 (en) DEVICES, SYSTEMS AND METHODS FOR INCREASING THE INTRALUMINAL DRUG DELIVERY AND RECEIVING
EP3440579A4 (en) INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3373977A4 (en) CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2020005472A (es) Sistemas de administración de fármacos a base de maitansinoide.
MX2022013237A (es) Maltodextrinas entrelazadas para el suministro oral de activos biologicos.
EP3137011A4 (en) Endodontic treatment with long term drug delivery system
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
PH12017501979A1 (en) Pharmaceutical compound
PH12017500084A1 (en) Vitamin b2 and its use